We assessed DFMO PK for comparison with plasma concentrations achieved in preclinical mouse models that demonstrate anti-neuroblastoma efficacy, ODC1 functional polymorphisms [25–27], and preliminary anti-tumor activity for this combination. The gene discussed is ODC1; the disease is neuroblastoma.